Dal epidemiologist shows probiotics prevent C. difficile in hospital

May 16, 2018 by Elissa Barnard, Dalhousie University
Dal epidemiologist shows probiotics prevent C. difficile in hospital
Dr. Bradley Johnston of Dal's Department of Community Health & Epidemiology. Credit: Jollymore photo

Hospitalized patients at high risk for C. difficile infection—a species of bacterium with symptoms that range from diarrhea to life-threatening inflammation of a colon—should be recommended probiotics, says Dr. Bradley Johnston.

An associate professor in the Department of Community Health & Epidemiology at Dalhousie Medical School, Dr. Johnston led a meta-analysis comparing data from 18 clinical trials in nine countries to see if probiotics could prevent C. difficile infection in hospitalized .

The infection is most common in hospitals where elderly patients have compromised immune systems and are on antibiotics.

The results, published in April in the peer-reviewed journal Infection Control & Hospital Epidemiology show that certain multi-species probiotics reduce the odds of C. difficile infection by about two-thirds—particularly among patients on two or more antibiotics.

At the same time, there were no safety concerns with any of the probiotics covered in the study among patients who are not immune-compromised.

"Our results suggest these probiotics are a safe and effective addition to C. difficile-prevention protocols in hospitals," says Dr. Johnston, "particularly among hospitals experiencing an outbreak of C. difficile."

All hospitals in Canada have robust strategies for preventing and managing C. difficile outbreaks, including such measures as isolating patients with suspected cases, intensive cleaning with disinfectant agents, and multi-faceted prevention and containment programs known as "antimicrobial stewardship interventions." Probiotics have rarely been included in any of these measures to date.

"The question is, 'Why don't hospitals use probiotics?' and the answer usually is, 'Well, what strain or species should we use?'" Dr. Johnston notes. "My answer is that we've done the meta-analysis and found no statistically significant difference across the probiotic species and strains in the studies we analyzed."

Not only is it is better for the patient to prevent the infection in the first place, it is likely cheaper. "Some of the drugs used to treat C. difficile cost upwards of $2,000 to fill a script," says Dr. Johnston, adding, "Probiotics cost from $20 to $40."

What is C. difficile?

C. difficile, short for Clostridium difficile, is a species of spore-forming bacterium.

"Antibiotics are one of the main risk factors for acquiring C. difficile," says Dr. Ian Davis, an assistant professor in the Division of Infectious Diseases at Dalhousie Medical School, noting its prevalence in hospitals with elderly patients who have compromised immune systems and are on antibiotics. "It's an opportunistic bug. If you are healthy and your intestinal flora is robust, it's unlikely C. difficile will get in and establish itself."

When antibiotics deplete bacterial flora, it creates space for the bacterium to flourish, although not everyone who acquires the organism will develop symptoms.

In 2017, C. difficile infection rates were 5.1 per 10,000 patient days across Canada and 2.39 per 10,000 patient days in Nova Scotia. Death directly attributed to C. difficile infection is in the one-to-two per cent range, occurring most commonly in older people and those compromised by other medical problems.

C. difficile infection is treated with antibiotics. Metronidazole costs tens of dollars, the more effective vancomycin a few hundred dollars, and the newer fidaxomicin about $2,000 per prescription. In rarer cases, people who've had recurring infections in spite of optimal antibiotic treatment have received fecal transplants to eradicate the bacterium.

While C. difficile has been well-controlled in Nova Scotia, the province's health-care system still faces challenges in fighting the in an aging population, in educating health-care consumers and providers in the best use of antibiotics and, as this study indicates, in adopting probiotics as a prevention strategy—particularly in those at higher risk.

The role of probiotics

Probiotics are live bacteria and yeasts that can support people's health—in particular, their digestive systems.

"The probiotic products studied have numerous mechanisms of action, including anti-bacterial, anti-viral and anti-diarrheal, as well as an ability to improve the integrity of the gut lining," says Dr. Johnston, noting that, "Further research is needed to uncover the mechanism for most probiotics."

Probiotics can be taken as a yogurt, in a capsule or as a powder in food or drinks. What's important is choosing the ones that have the most reliable data on efficacy and safety, and getting an effective dose.

Running out to buy yogurt is not the solution. "The probiotic dose is very low among yogurts found in grocery stores and hasn't been studied for the prevention of C. difficile," Dr. Johnston says. "There are higher-dose probiotic products with evidence of efficacy for C. difficile found in some health food stores though."

Many physicians ask their patients to take probiotics if they're entering hospital, but official guidelines by authoritative organizations do not make any such recommendations.

"From my perspective, this information should be offered to high-risk patients and their families," Dr. Johnston says. "Patients are likely to value the potential risk reductions in C. difficile that certain probiotics offer."

Experts estimate it can take 15 to 20 years to change clinical practice, even in the face of solid evidence. "This evidence has been accumulating over the past 15 years, so maybe we're almost there with respect to patients at high risk," Dr. Johnston says.

Detailed analysis provides clear answers

Dr. Johnston's team asked investigators from Sweden, Poland, the U.S., the U.K., Turkey and Chile for access to their raw data. This encompassed 18 randomized trials involving 6,851 study participants, and some of the largest probiotic trials ever conducted.

"Gaining access to the raw data allowed us to conduct a detailed analysis and determine that multi-species probiotics given to patients on two or more antibiotics may have the greatest effect," he says. "Based on our analysis, if you administer certain probiotics to 1,000 high-risk patients, you will prevent 81 cases of C. difficile."

More research is needed to identify those high-risk populations that may benefit most from probiotics—for example, patients known to be colonized with C. difficile—and to explore the potential use of probiotics in immune-compromised patients, Dr. Johnston says.

"We have compelling evidence that some probiotics work to prevent C. difficile in certain hospital populations and, moreover, that they're safe among those with normal immune function."

Explore further: Probiotics useful in the fight against infection prevention

Related Stories

Probiotics useful in the fight against infection prevention

April 26, 2018
Probiotics may be a relatively safe, simple, and low-cost solution for preventing Clostridium difficile infections (CDI) in hospital settings, according to two studies published today in Infection Control & Hospital Epidemiology, ...

Probiotics prevent diarrhoea related to antibiotic use

May 30, 2013
Probiotic supplements have the potential to prevent diarrhoea caused by antibiotics, according to a new Cochrane systematic review. The authors studied Clostridium difficile (C. difficile) infections in patients taking antibiotics ...

Probiotics show potential to minimize C. difficile

November 13, 2012
(Medical Xpress)—New cases of C. difficile-associated diarrhea among hospitalized patients taking antibiotics can be reduced by two-thirds with the use of probiotics, according to new research published Monday in the Annals ...

Can probiotics reduce the severity of C. difficile infections?

August 7, 2014
Probiotics have shown promise for treating patients with recurrent Clostridium difficile infections. However, their safety and quality control requires further study – especially in immunocompromised patients, concludes ...

Metabolite therapy proves effective in treating C. difficile in mice

March 20, 2018
A team of UCLA researchers found that a metabolite therapy was effective in mice for treating a serious infection of the colon known as Clostridium difficile infection, or C. difficile.

Recommended for you

Marker may help target treatments for Crohn's patients

October 16, 2018
Crohn's disease (CD), a chronic inflammatory condition of the intestinal tract, has emerged as a global disease, with rates steadily increasing over the last 50 years. Experts have long suspected that CD likely represents ...

Polio: Environmental monitoring will be key as world reaches global eradication

October 15, 2018
Robust environmental monitoring should be used as the world approaches global eradication of polio, say University of Michigan researchers who recently studied the epidemiology of the 2013 silent polio outbreak in Rahat, ...

Study traces hospital-acquired bloodstream infections to patients' own bodies

October 15, 2018
The most common source of a bloodstream infection acquired during a hospital stay is not a nurse's or doctor's dirty hands, or another patient's sneeze or visitor's cough, but the patient's own gut, Stanford University School ...

Researchers make essential imaging tests safer for people at risk of acute kidney injury

October 15, 2018
Every year, millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes. "For the majority of patients, these are safe and necessary procedures. However, about ...

Medical marijuana might help MS patients, but uncertainty remains

October 13, 2018
Medical products derived from marijuana might have a mild benefit in treating symptoms of multiple sclerosis, based on reports from patients.

Do not give decongestants to young children for common cold symptoms, say experts

October 11, 2018
Decongestants should not be given to children under 6—and given with caution in children under 12—as there is no evidence that they alleviate symptoms such as a blocked or runny nose, and their safety is unclear, say ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.